

Special Issue

Personalized Medicine in Women's Cancer

Message from the Guest Editor

Precision medicine for cancer care individualizes treatment regimens through predictive and prognostic assessment of the risk of recurrence or progression for each individual's tumor. Precision should be sought for each phase of care, from detection, to diagnosis, to treatment and to survivorship. Personalization is achieved by quantifying the inherent biological behaviors of each tumor, in contradiction to the traditional diagnostic and prognostic estimations based on clinicopathologic features. Extensive research focused on women's cancers, including breast, ovarian and other gynecologic cancers, is being conducted in multiple disciplines. Clinical trial design is adapting to the new paradigms of patient selection based on tumor-specific molecular assays rather than grouping heterogenous patient populations into two or three comparison arms. This Special Issue of the *Journal of Personalized Medicine* aims to highlight the current state of the science and showcase some of the latest findings in the field of precision medicine research and advances in the diagnosis and treatment of Women's Cancers.

Guest Editor

Dr. Eleanor E. R. Harris

University Hospitals Case Western Reserve University, Cleveland, OH, USA

Deadline for manuscript submissions

closed (28 February 2021)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/54708

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).